EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer ...
AstraZeneca (LSE:AZN) has seen a shift recently with the EU approval of ENHERTU® and Imfinzi®, which are likely influential ...
The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing ...
The EC based its decision on data from the DESTINY-Breast06 trial, which included patients whose tumors had very low levels of HER2 expression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback